| Daniel Keith Harrison, MD | |
|
924 Montclair Rd, Suite 200, Birmingham, AL 35213-1211 | |
| (205) 591-7999 | |
| (205) 591-5051 |
| Full Name | Daniel Keith Harrison |
|---|---|
| Gender | Male |
| Speciality | Pathology - Anatomic Pathology & Clinical Pathology |
| Location | 924 Montclair Rd, Birmingham, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063622280 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZN0500X | Pathology - Neuropathology | 26380 (Alabama) | Secondary |
| 207ZP0102X | Pathology - Anatomic Pathology & Clinical Pathology | 26380 (Alabama) | Primary |
| Entity Name | Gastro Care Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114039872 PECOS PAC ID: 4981687712 Enrollment ID: O20040611000282 |
News Archive
A Texas A&M AgriLife Research team has good news for patients with copper-deficiency disorders, especially young children diagnosed with Menkes disease.
BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
› Verified 2 days ago
| Entity Name | Urology Centers Of Alabama Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710962550 PECOS PAC ID: 0941264345 Enrollment ID: O20041116000389 |
News Archive
A Texas A&M AgriLife Research team has good news for patients with copper-deficiency disorders, especially young children diagnosed with Menkes disease.
BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
› Verified 2 days ago
| Entity Name | Birmingham Gastroenterology Associates Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366406514 PECOS PAC ID: 9537107594 Enrollment ID: O20050420000545 |
News Archive
A Texas A&M AgriLife Research team has good news for patients with copper-deficiency disorders, especially young children diagnosed with Menkes disease.
BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
› Verified 2 days ago
| Entity Name | Cunningham Pathology, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831195437 PECOS PAC ID: 2668468802 Enrollment ID: O20080218000071 |
News Archive
A Texas A&M AgriLife Research team has good news for patients with copper-deficiency disorders, especially young children diagnosed with Menkes disease.
BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Daniel Keith Harrison, MD 924 Montclair Rd, Suite 200, Birmingham, AL 35213-1211 Ph: (205) 591-7999 | Daniel Keith Harrison, MD 924 Montclair Rd, Suite 200, Birmingham, AL 35213-1211 Ph: (205) 591-7999 |
News Archive
A Texas A&M AgriLife Research team has good news for patients with copper-deficiency disorders, especially young children diagnosed with Menkes disease.
BioCurex, Inc. today announced that it has filed a new patent within the Patent Cooperation Treaty, which presently includes 142 countries.
A team of nine researchers based in the United States and Burkina Faso will receive the 2019 Newcomb Cleveland Prize, presented by the American Association for the Advancement of Science, for the development of a promising tool in the global fight against malaria and other diseases transmitted by mosquitoes, including dengue and Zika.
So-called "triple-negative" breast cancer is a particularly aggressive and difficult-to-treat form. It accounts for only about 10 percent of breast cancer cases, but is responsible for about 25 percent of breast cancer fatalities.
ADVANCELL, an emerging biopharmaceutical company, today announced positive results from a clinical study conducted with Acadra (Acadesine) in Chronic Lymphocytic Leukemia patients resistant to current therapies. The company also announced promising non-clinical results in Multiple Myeloma (MM), Mantle Cell Lymphoma (MCL) and other lymphoproliferative disorders. Synergism of Acadra in combination with current treatment in these indications has been demonstrated.
› Verified 2 days ago
Dr. Kyle Charles Mills, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2800 Fax: 205-949-2801 | |
Leona Council, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th St S, Birmingham, AL 35249 Phone: 205-934-5038 | |
Dr. Alexander Wong, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 3550 Independence Dr, Birmingham, AL 35209 Phone: 205-949-2806 Fax: 205-949-2875 | |
Dr. David Ullman, M.D. Pathology Medicare: Medicare Enrolled Practice Location: 625 19th St S, Birmingham, AL 35233 Phone: 205-934-4977 | |
Dr. Jonathan G Phillips, MD Pathology Medicare: Medicare Enrolled Practice Location: 924 Montclair Rd, Ste 200, Birmingham, AL 35213 Phone: 205-591-7999 Fax: 205-591-5051 | |
Thomas S Winokur, MD Pathology Medicare: Accepting Medicare Assignments Practice Location: 619 19th Street South, Birmingham, AL 35233 Phone: 205-934-6600 | |
Isam Eltoum, Pathology Medicare: Accepting Medicare Assignments Practice Location: 2000 6th Ave S, Birmingham, AL 35233 Phone: 205-934-9999 |